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Zinc-a2-glycoprotein (ZAG) is an adipokine with an MHC class I-like protein fold. Even though zinc
causes ZAG to precipitate from plasma during protein puriﬁcation, no zinc binding has been
identiﬁed to date. Using mass spectrometry, we demonstrated that ZAG contains one strongly bound
zinc ion, predicted to lie close to the a1 and a2 helical groove. UV, CD and ﬂuorescence spectrosco-
pies detected weak zinc binding to holo-ZAG, which can bind up to 15 zinc ions. Zinc binding to
11-(dansylamino) undecanoic acid was enhanced by holo-ZAG. Zinc binding may be important for
ZAG binding to fatty acids and the b-adrenergic receptor.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Zinc-a2-glycoprotein (ZAG), ﬁrst identiﬁed in 1961, derives its
name from its precipitation from human plasma upon addition of
zinc acetate [1]. ZAG has since been found in secretory epithelial
cells and body ﬂuids, and is identical to a lipid mobilizing factor
isolated from the urine of patients with cancer cachexia that
stimulates lipolysis [2]. Due to its expression in and secretion from
adipocytes, ZAG is considered an adipokine. ZAG expression in
adipocytes is inversely related to fat mass, thus it helps maintain
body weight in mice and humans [2]. Epidemiological studies have
linked ZAG and plasma cholesterol [2]. The non-synonymous single
nucleotide polymorphism rs4215 in ZAG is associated with plasma
cholesterol and obesity [2]. Therefore, characterizing how ZAG
interacts with its ligands is critical for understanding its molecular
mechanism in the control of body fat mass.
Structurally ZAG possesses a class I major histocompatibility
complex (MHC) fold [3]. It is distinct however from other membersof this protein family: it is soluble, rather than anchored to plasma
membranes, and associates with prolactin inducible protein rather
than b2-microglobulin. Like class I MHC molecules, ZAG possesses
an open groove between its a1 and a2 domain helices. The original
crystal structure of ZAG revealed unidentiﬁable electron density in
a similar position to that occupied by antigenic peptides in classi-
cal MHC proteins. Residues within 4.5 Å of this density were
hydrophobic with the exception of Arg73. Our subsequent work
revealed the unidentiﬁed electron density is polyethylene glycol,
an adjuvant used during crystallization [4]. Calorimetry and
ﬂuorescence spectroscopy revealed that ZAG binds hydrophobic
ligands, particularly polyunsaturated fatty acids [5]. Our alanine
scanning site-directed mutagenesis conﬁrmed that the ZAG groove
was indeed the location of fatty acid binding [6].
Since none of the ZAG crystal structures in the Protein Data
Bank revealed bound zinc [3,4], we examined the zinc binding
properties of ZAG. We show that recombinant human ZAG contains
one tightly-bound zinc ion that is inaccessible to chelating agents
in the absence of chaotropic agents. Based on computational
modeling and sequence conservation, we predict the strongly
bound zinc is located close to the a1 and a2 helical groove.
Additional weak zinc binding causes ZAG to precipitate. We also
show that zinc binds to 11-(dansylamino) undecanoic acid, and
that the interaction is enhanced by holo-ZAG.
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2.1. Protein puriﬁcation
An Escherichia coli pET23a clone, engineered to express human
ZAG, was puriﬁed to apparent homogeneity following release from
inclusion bodies using 8 M guanidinium hydrochloride (GdnHCl).
The unfolded protein was gradually added to 1 l of refolding buffer
(0.1 M Tris, 2 mM EDTA, 0.4 M L-arginine hydrochloride, 0.5 mM
oxidised glutathione, 5 mM reduced glutathione) and left at 4 C
overnight to equilibrate. ZAG was concentrated to 10 ml using
Vivaspin 20 (Sartorius) centrifugal concentrators and dialyzed
against 1 l of 10 mM Hepes, 137 mM NaCl, pH 7.4 with three buffer
changes. Its purity was conﬁrmed by a single band on SDS–PAGE
and single peaks observed in gel ﬁltration and size distribution
analysis from a sedimentation velocity experiment (Fig. S1). ZAG
was subsequently stored at 20 C and thawed before experimen-
tal use. Protein concentrations were determined spectrophotomet-
rically using a Lambda 25 UV/vis spectrophotometer (PerkinElmer,
USA), with a theoretical e280 value of 71071 M1 cm1 (calculated
from the amino acid composition) and a molecular mass of 32
276 Da.
2.2. Inductively coupled plasma-mass spectrometry (ICP-MS)
To quantify the number of zinc ions associated with ZAG, four
ZAG preparations were subjected to ICP-MS. The ﬁrst sample was
recombinant human ZAG, prepared as above, and dialyzed against
10 mM Hepes, pH 7.4. The second sample was dialyzed against
10 mM Hepes, pH 7.4 containing 1 g/l of Chelex 100 (Bio-Rad).
The third was prepared from 3 ml of 6 M GdnHCl denatured ZAG
incubated under shaking conditions with 1 g of Chelex 100 resin
for 2 h at 25 C. The protein-resin solution was spun at 1500g
for 3 min, and the supernatant added to 1 l of refolding buffer as
described above. After concentration, the Chelex 100 treated pro-
tein was dialyzed against 10 mM Hepes, pH 7.4, 1 g/l of Chelex
100 resin. For the fourth ZAG preparation, ZAG was dialyzed
against 10 mM Hepes, pH 7.4 containing 2 mM ZnCl2. For all prep-
arations 1 ml protein was dialyzed against 1 l of buffer. A Perkin El-
mer Elan 6100DRC ICP-MS was used to determine the
concentration of metal ions in 1 ml samples, run in triplicate.
ZAG 7.5 lMwas analyzed for each sample and the dialyzed buffers
also analyzed. Measurements in ppb were converted to lM, the
buffer metal content was subtracted, and data were normalized
to the protein concentration. By ICP-MS, MilliQ water, in which
all buffers were prepared, was found to have no signiﬁcant traces
of zinc, copper or iron and 0.342 ± 0.08 lM calcium (mean ± S.D.,
n = 3).
2.3. Molecular modelling
The ZAG crystal structure at 2.5 Å resolution (PDB code 1ZAG)
was scanned using a custom-written Perl script to identify clusters
of side chain oxygen, nitrogen and sulfur atoms within 8.4 Å of
each other. The output was examined for groups of conserved his-
tidine, cysteine, aspartate and glutamate residues, identiﬁed by se-
quence alignment. For molecular dynamics simulations (MDS),
residues 5–277 were included, default protonation states used
for all ionisable residues, and the N- and C-terminals amidated
and acetylated respectively. The system was solvated and ions ran-
domly positioned up to a concentration of 500 mM ZnCl2. The ﬁnal
system was charge neutral. NAMD was used for the simulations
with the CHARMM27 force ﬁeld with CMAP corrections, and the
TIP3P model for water molecules. Standard parameters for ions
in the CHARMM27 force ﬁeld were adopted. Simulations wereperformed in the NpT ensemble. Pressure was kept at 1 atm by
the Nose-Hoover Langevin piston, with a damping time constant
of 100 ps and a period of 200 ps. Temperature was kept at 298 K
by coupling to a Langevin thermostat, with a damping coefﬁcient
of 5 ps1. Electrostatic interactions were treated by the Particle
Mesh Ewald algorithm, with grid spacing below 1 Å. Van der Waals
interactions were truncated at 12 Å, and smoothed at 10 Å. Hydro-
gen atoms were restrained by the SETTLE algorithm, which allowed
a 2 fs time-step. The total production run was 350 ns.
2.4. Circular dichroism (CD)
UV absorption and CD spectra were acquired on an Applied
Photophysics Chirascan Plus™ spectrometer (Leatherhead, UK).
10 mm and 0.5 mm rectangular cells were employed in the 400–
230 nm and 260–180 nm regions respectively, and the instrument
ﬂushed continuously with nitrogen gas. All spectra were recorded
using a 1 nm spectral bandwidth, 1 nm step size and a 1.5 s instru-
ment time-per-point prior to buffer baseline subtraction. All
measurements were made at 23 C using 0.2 mg/ml protein and
ZnCl2 solutions in 50 mM Hepes pH 7.4. Protein concentrations
were calculated based upon the A280 reading (after applying a light
scattering correction embedded in the Grams/32 AI software).
Titration curves were ﬁtted to a single noncompetitive binding
model (Table S1) generating Ka values.
2.5. Fluorescence
Fluorescence measurements were recorded at 22 C with a Per-
kin Elmer LS50B Luminscence Spectrometer (Bucks, UK) using 2 ml
samples in 10 mM Hepes, 137 mM NaCl, pH 7.4 in a quartz cuvette.
Intrinsic tryptophan ﬂuorescence emission spectra of 0.12 lM ZAG
(kexc = 290 nm) were recorded and changes in ﬂuorescence emis-
sion noted upon subsequent additions of 0.1, 0.4 and 5.8 lM ZnCl2.
As a control, equivalent additions of ZnCl2 were made to a 0.12 lM
solution of n-acetyl DL-tryptophan amide. The fatty acid DAUDA
(11-(dansylamino) undecanoic acid; Molecular Probes, Eugene,
OR) was stored as a 0.3 mM stock solution in ethanol in the dark
at 20 C. The ﬂuorescence emission intensity of 0.75 lM DAUDA
(kexc = 345 nm) was recorded upon addition of 0.75 lM ZAG.
Increasing amounts of 20 mM divalent metal chloride were added
to the preformed ZAG:DAUDA complex and the decrease in ﬂuores-
cence intensity observed at 523 nm. Titration curves were ﬁtted
using standard nonlinear regression techniques to a single non-
competitive binding model (Table S1) generating Kd values. Con-
trols involved titration of 0.75 lM DAUDA (kexc = 345 nm) with
20 mM stock solutions of other divalent metal chlorides. Fluores-
cence spectra were corrected for the effects of dilution and, where
noted, solvent Raman scattering was corrected by subtracting the
buffer-only spectrum.
3. Results
3.1. Stoichiometry of Zn2+ binding to ZAG
The Zn2+ content in ZAG was measured using inductively cou-
pled plasma-mass spectrometry (ICP-MS; Fig. 1). Puriﬁed recombi-
nant human ZAG was found to contain one molar equivalent of
Zn2+ (1.18 ± 0.08; mean ± S.D., n = 3). Almost no Cu2+ and Fe2+ were
detected while approximately 2 molar equivalents of Ca2+ was de-
tected (Fig. 1A). Addition of the chelating ion exchange resin Che-
lex to the dialysis buffer did not remove this intrinsically bound
Zn2+ ion (Fig. 2B). Zinc was however removed upon incubation of
denatured ZAG with Chelex, followed by refolding, indicating that
puriﬁed recombinant ZAG contains one high afﬁnity zinc binding
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Fig. 1. Stoichiometry of zinc-ZAG binding using ICP-MS. (A) Amounts of divalent cations in recombinant ZAG. (B) Amounts of Zn2+ in four recombinant ZAG preparations; Z:
dialyzed ZAG; DZ: ZAG dialyzed against Chelex; UZ: denatured ZAG incubated with Chelex prior to refolding and dialysis against Chelex containing buffer; EDZ: ZAG dialyzed
against ZnCl2 containing buffer.
Fig. 2. MDS of Zn2+ association with ZAG. (A) Time dependence of the co-ordination bond lengths of Asp90, His95 and Asp120 with Zn during the simulation. (B) The root-
mean-square deviations (RMSD) of the Ca atoms of ZAG relative to their starting structure as a function of time. (C) Number of zinc ions associated with ZAG over time. (D)
Putative locations of strong (red arrow) and weak (grey) zinc binding sites taken from the snapshot at 140 ns.
A.A. Kumar et al. / FEBS Letters 587 (2013) 3949–3954 3951site that is not accessible to Chelex in the folded state. Equilibrium
dialysis was performed to analyze the total number of Zn2+ binding
sites in ZAG. When dialyzed against 2 mM ZnCl2, ICP-MS showed
that ZAG contained 16.2 ± 0.1 (n = 3) molar equivalents of Zn2+ at
pH 7.4. UV absorption showed the protein began to precipitate un-
der these conditions (see Section 3.3). This result suggests there are
at least 15 weak Zn2+ binding sites in ZAG in addition to the high
afﬁnity one.3.2. Prediction of zinc binding sites
Computational scanning of the ZAG crystal structure predicted
four potential strong zinc binding sites in the a1 and a2 domains.
One contained Asp90, His95 and Asp120, two consisted of one Glu
and two Asp, and one consisted of three Glu residues. All four pre-
dicted sites were strictly conserved in a sequence alignment of ZAG
from six different species (Fig. S2). The ﬁrst of the four sites was
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Fig. 4. Changes in tryptophan ﬂuorescence emission (kexc = 290 nm) upon additions
of ZnCl2 to 0.12 lM ZAG in 10 mMHepes, 137 mM NaCl buffer, pH 7.4. Spectra were
corrected for Raman scattering and are representative of two individual
experiments.
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During a 100 ns time period in MDS, both side chain oxygens of
Asp120 remained in close proximity (2 Å) to the predicted zinc site
(Fig. 3A), those of Asp90 were within approximately 4 Å, and occa-
sionally the Nd1 atom of His95 was less than 5 Å away. During MDS,
the b-sheet, coil and turn secondary structures changed over time
while the a-helices remained unchanged (Fig. 2B). Asp90 and
His95 are located on the loop joining the a1 helix to strand b1 of
the a2 domain, while Asp120 is located on a turn joining the b2
and b3 strands in the a2 domain. The secondary structures ﬂuctu-
ated with time to suggest that a tetrahedral geometry with appro-
priate zinc-ligand distances may form around the predicted zinc
site. MDS further showed that, between 80 ns and 140 ns, the aver-
age number of zinc ions within 4.5 Å of possible donor atoms from
ZAG was 13 ± 2 with a maximum count of 18 (Fig. 2C). This is in
good agreement with the ICP-MS analyses. At 140 ns, MDS showed
that, within 4.5 Å of ZAG, the strong binding site was close to its
ligand-binding groove while the 12 weak binding sites (typically
single acidic residues) were positioned all over the protein
(Fig. 2D).
3.3. Weak Zn2+ binding to ZAG
Conformational changes and/or aggregation following zinc
binding to recombinant holo-ZAG (zinc-ZAG) were followed using
UV and CD. The addition of 905 lM ZnCl2 to a constant concentra-
tion of 6.2 lM ZAG increased the UV absorption, indicating the
beginning of aggregation (Fig. 3A). The tertiary structure remained
unchanged until additions of 1495 lM and 1784 lM ZnCl2
decreased the near-UV CD (Fig. 3B). The far-UV CD spectra re-
mained unchanged up to 471 lM ZnCl2 (Fig. 3C). Further additions
of up to 1348 lM ZnCl2 caused a decrease in the far-UV CD spectra-0.0
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ZAG dissociation constant Kd, the changes in the far-UV CD signal
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of the weak binding sites (Fig. 3D).
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does not affect the ﬂuorescence emission of N-acetyl D,L-trypto-
phan amide (Fig. S3). No blue shift in tryptophan emission was
observed upon addition of Zn2+, thus formation of the zinc-ZAG
complex did not alter the tryptophan environment [7].
3.4. Divalent metal binding to DAUDA and the ZAG:DAUDA complex
The free dansylated fatty acid DAUDA has low ﬂuorescence
intensity with a maximum emission at 550 nm (Fig. 5A). The
addition of ZnCl2 to DAUDA decreased its ﬂuorescence emission
intensity and the emission wavelength shifted from 550 to
547 nm (Fig. 5A). Presumably zinc associates with the deproto-
nated carboxylic acid and N14 atom of DAUDA (Fig. S4). This static
quenching effect is likely due to photoinduced electron transfer
caused by removal of the proton at N14 by zinc in its capacity as
a strong Lewis acid and the wavelength shift by steric hindrance
of P electrons. Fitting the titration curve (Fig. 5B) yields a Kd of
432 ± 64 lM for zinc-DAUDA (Table 1).
ZAG binds DAUDA in the groove between the a1 and a2 helices
[6]. Upon addition of ZAG, the DAUDA emission undergoes a blue
shift from 552 to 536 nm with an increase in emission intensity,
indicating that DAUDA resides in a more hydrophobic environ-
ment. The addition of ZnCl2 to ZAG-DAUDA causes a further de-
crease in emission intensity and a progressive blue shift in
ﬂuorescence emission from 523 to 519 nm (Fig. 6A). A standard
hyperbolic/non-cooperative binding model based on a 1:1:1 stoi-
chiometry gave a ZAG:DAUDA:Zn dissociation constant of
128 ± 25 lM (Fig. 6B, Table 1). The reduction of afﬁnity from
432 lM (see above) showed that zinc binding to DAUDA was en-
hanced by ZAG. Cobalt, nickel, manganese and barium all bound
to DAUDA (Fig. 4C) with Kd values of 126–146 lM (Table 1). Even
though the quenching showed similar Kd values for these metals
with or without ZAG, only zinc resulted in stronger binding of
DAUDA to ZAG (Table 1). This showed that zinc-ZAG binding af-
fects its ability to bind lipid in the a1 and a2 helical groove.
4. Discussion
Here, we report the ﬁrst observation of a tightly-bound zinc
atom in ZAG. The source of zinc is attributed to the media in which
the ZAG-containing E. coli construct was grown [8]. Other proteins
acquire zinc during expression in E. coli [9,10]. The tightly-bound
zinc remains in situ despite refolding of denatured ZAG in the pres-
ence of 2 mM EDTA. Presumably denatured ZAG immediately folds
to encapsulate zinc, preventing its sequestration by EDTA. The
divalent metal sequestering agent Chelex is also unable to remove
this zinc ion, unless Chelex is incubated with denatured ZAG prior
to refolding. Thus, the name ZAG remains appropriate. This phe-
nomenon has been observed with other proteins; EDTA is unable
to remove the two tightly bound Zn ions in E. coli RPase [11]. NoTable 1
Divalent metal binding to DAUDA and the DAUDA:ZAG complex.
Divalent metal Kd (lM) ± S.D.
DAUDA
n = 1
DAUDA:ZAG
n = 1
Barium 126 ± 29 131 ± 21
Manganese 137 ± 20 120 ± 18
Cobalt 146 ± 34 123 ± 22
Nickel 131 ± 21 191 ± 33
Zinc 432 ± 64 128±25a
Dissociation constants (Kd) were determined from ﬂuorescence titration curves
Fig. 5C and Fig. 6C.
a Representative of three individual experiments.zinc ions had been reported in earlier crystal structures of ZAG,
although they might have been missed in the electron density
maps due to low occupancy. A strong zinc binding site, predicted
to lie close to the lipid-binding helical groove of ZAG, uses
Asp90, His95 and Asp120 as Zn2+ ligands. These residues are con-
served in other mammalian sequences. A related sequence motif,
Asp160-His198-Asp200, in the exotoxin SPE-H from Streptococcus
pyogenes [12] binds zinc. Also, the spacing of the amino acids, with
a short spacer between two amino acids followed by a longer
spacer is typical for many zinc binding sites [13]. These observa-
tions lend credibility to our prediction.
Our results explain how ZAG obtained its name through addi-
tional zinc binding. Because the pI of ZAG is 5.6, zinc binding would
affect this pI. Puriﬁed holo-ZAG begins to precipitate at zinc con-
centrations of 905 lM, this being reversed upon addition of EDTA.
Zinc binds weakly to holo-ZAG with a Kd of 100 lM. Total plasma
zinc is about 14.7 lM [14] of which the majority is bound to serum
albumin [15]. Bioavailable zinc in blood plasma is therefore around
20–210 pM [16], insufﬁcient to induce ZAG precipitation. The 15
weak binding sites are located in all regions of the protein. A sim-
ilar zinc induced precipitation has been observed with comple-
ment proteins [17].
The effects of zinc and four other divalent metals on binding to
the ﬂuorescently-tagged fatty acid DAUDA were tested in the pres-
ence and absence of holo-ZAG. All ﬁve metals bound to DAUDA
with lM afﬁnity (Kd). Zinc was the only tested metal that showed
enhanced DAUDA binding in the presence of ZAG. Presumably the
bound conformation of DAUDA within ZAG facilitates zinc binding.
A three dimensional model of DAUDA docked in ZAG showed that
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3954 A.A. Kumar et al. / FEBS Letters 587 (2013) 3949–3954Glu79 (Oe1) was within 4.5 Å of DAUDA. This residue is not
conserved across species (Fig. S2) but represents another site on
human ZAG capable of binding zinc.
Given that the ligands for ZAG include long chain polyunsatu-
rated fatty acids [5] and the b adrenergic receptor [18,19], it will
be of great interest to know if zinc at its strong site in ZAG alters
the afﬁnity of ZAG for these additional ligands.
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